Quote this publication Share Print


Opinions on drugs - Posted on Nov 08 2006

Reason for request

Inclusion on the list of medicines approved for use by hospitals in the extension of indication: MabThera® maintenance therapy is indicated for patients with relapsed or refractory follicular lymphoma responding to induction therapy with chemotherapy with or without MabThera®.


Clinical Benefit


The actual benefit of MabThera® in the context of maintenance treatment for non-Hodgkin’s follicular lymphoma is substantial.

Clinical Added Value


In maintenance treatment for relapsed or refractory follicular lymphoma, MabThera® provides a major IAB (IAB I) in terms of efficacy compared with the current treatment strategy.

Contact Us

Évaluation des médicaments